Q-omics provides the consensus-scored TTC32 profile across patient tissues and cancer cell-line models. TTC32 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TTC32 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, TTC32 RNA expression shows 19,855 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where TTC32 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC32 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC32 survival associations across molecular data types. TTC32 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC32 RNA expression–survival associations across cancer types. High TTC32 expression shows unfavorable associations in ACC, KIRC and UVM, but favorable associations in UCS, OV and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TTC32 RNA expression.
This table summarizes TTC32 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TTC32. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC32 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, COAD, BLCA and HNSC. The THCA box plot shows higher TTC32 RNA expression in normal versus tumor tissue (log2 FC = −0.388, t-test p < 0.001).
This table shows molecular features associated with TTC32 in patient tissues and cancer cell lines. In patient samples, TTC32 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC32 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
